Hologic, Inc.
TypePublic
IndustryMedical Technology
Founded1985 (1985)[1]
HeadquartersMarlborough, Massachusetts, U.S.
Key people
Revenue
  • Decrease US$4.86 billion (2022)
  • US$5.63 billion (2021)
  • Decrease US$1.64 billion (2022)
  • US$2.48 billion (2021)
  • Decrease US$1.30 billion (2022)
  • US$1.87 billion (2021)
Total assets
  • Increase US$9.07 billion (2022)
  • US$8.92 billion (2021)
Total equity
  • Increase US$4.88 billion (2022)
  • US$4.22 billion (2021)
Number of employees
6,944 (2022)
Websitehologic.com
Footnotes / references
[3]

Hologic, Inc. is a medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.[2]

History

In late November 2013, activist investor Carl Icahn disclosed a 12.5% stake in the company. Subsequently, the company adopted a poison pill to prevent a hostile takeover. In negotiations with the company's board of directors, two additional directors backed by Icahn were added to the board, each managing directors of Icahn holding companies.[4] Icahn considered his investment and intervention into Hologic to have been a success, with his nominees to the board of directors resigning on March 3, 2016[5] and exiting his position by May 16, 2016.[6]

In 2017, Hologic acquired Westford, Massachusetts-based aesthetic medicine company Cynosure for $1.65 billion.[7]

On November 20, 2019, Hologic announced the divestment of Cynosure to Clayton, Dubilier & Rice for $205 million;[8] this was completed on December 30, 2019.[9] Cynosure had ~825 employees at the time of the divestiture.[10][7]

In March 2020, Hologic received emergency use authorization from the FDA for a test for SARS-CoV-2 to help mitigate the COVID-19 pandemic.[11] In May 2020, Hologic received a second emergency use authorization from the FDA for 2019-nCov to increase potential throughput of testing.[12]

In June 2020, Hologic collaborated with Grifols, a global producer of plasma-driven medicines, to increase Spain's testing capacity for COVID-19.[13]

In November 2020, Hologic won a $119 million contract from the U.S. Department of Health and Human Services and the Department of Defense to help expand production facilities in three states, Wisconsin, Maine and California, with the goal to provide 13 million COVID tests per month by January 2022.[14][15]

In January 2021, the company announced it would acquire Biotheranostics and its breast and metastatic cancer test portfolio for $230 million[16] and SOMATEX for $64 Million.[17]

In April 2021, the company announced it will acquire Mobidiag, a molecular diagnostics firm with multiplex technology, for $795 million.[18] The acquisition completed in June 2021.[19]

In March 2022, Hologic became the new title sponsor of the WTA Tour in women's professional tennis. As part of the sponsorship, the company was also named the "official health partner" of the Women's Tennis Association.[20]

References

  1. ↑ "Hologic, Inc. (HOLX)". Yahoo! Finance. Retrieved January 11, 2020.
  2. 1 2 3 4 "Hologic Inc. Profile". MarketWatch.com. Retrieved January 11, 2020.
  3. ↑ "Hologic, Inc. 2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. November 15, 2022.
  4. ↑ Grover, Natalie (December 9, 2013). "Hologic names new CEO, adds two Icahn nominees to board". Reuters.com. Archived from the original on October 1, 2018.
  5. ↑ Adams, Dan (March 4, 2016). "Carl Icahn cashes in on Hologic success". Boston Globe. Archived from the original on September 3, 2019. Retrieved January 6, 2020.
  6. ↑ Witkowski, Wallace (May 6, 2016). "Icahn exits Gannett, Hologic positions; adds to Xerox". MarketWatch.com. Archived from the original on July 5, 2017. Retrieved January 6, 2020.
  7. 1 2 Stempniak, Marty (January 3, 2020). "Breast imaging company Hologic unloads aesthetics line at $1B-plus loss". RadiologyBusiness.com. Archived from the original on January 6, 2020. Retrieved January 5, 2020.
  8. ↑ "Hologic to Sell Cynosure Medical Aesthetics Business to Clayton, Dubilier & Rice". BusinessWire.com. November 20, 2019. Retrieved January 11, 2020.
  9. ↑ "Hologic Completes Divestiture of Cynosure Medical Aesthetics Business". Yahoo! Finance. Business Wire. December 30, 2019. Retrieved January 5, 2020.
  10. ↑ "Hologic (HOLX) Divests Cynosure to Focus on Women's Health". Zacks.com. January 2, 2020. Archived from the original on January 6, 2020. Retrieved January 5, 2020.
  11. ↑ "FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits". IBTimes.com. 19 March 2020. Archived from the original on 20 March 2020.
  12. ↑ "Hologic's latest COVID-19 test gets FDA approval for emergency use". reuters.com. 29 May 2020.
  13. ↑ "Hologic : Grifols and Hologic embark on a unique collaboration for COVID-19 testing in Spain". MarketScreener. Retrieved 2020-07-07.
  14. ↑ "Hologic nets $119M U.S. government contract to boost coronavirus test manufacturing into 2022". FierceBiotech. Retrieved 2020-11-04.
  15. ↑ "Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity". BaytownSun.com. Retrieved 2020-11-04.
  16. ↑ "Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 million".
  17. ↑ "Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies, for $64 Million".
  18. ↑ Vinluan, Frank (2021-04-08). "Hologic makes a multiplex molecular testing move with $795M Mobidiag acquisition". MedCity News. Retrieved 2021-04-26.
  19. ↑ "Hologic Completes Acquisition of Mobidiag" (Press release). Hologic. June 17, 2021 – via Business Wire.
  20. ↑ Clarey, Christopher (2022-03-03). "Strong Stance on China and Peng Shuai Helps Land WTA a New Title Sponsor". The New York Times. Retrieved 2022-03-03.
  • Official website Edit this at Wikidata
  • Business data for Hologic:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.